



Press Release

Louvain-la-Neuve, Belgium and Lalaye, France – January 6, 2016

PROTON THERAPY SALES ORDERS REACHED JUST OVER US\$ 1 BILLION IN 2015

MEDraysintell noticed that in 2015 the global proton therapy sales orders grew to record levels at just over US\$ 1 billion for a total of 58 proton therapy treatment rooms, more than twice as much as in 2014. Two companies commanded together almost half of these orders.

There is an increasing interest for one-room compact proton therapy centers which accounted for about 35% of the global orders.

By end of 2015, 174 particle therapy treatment rooms were operational worldwide, and projections by 2030 anticipate the proton therapy world market to reach between 1,200 and 1,800 treatment rooms worldwide.

There is a growing clinical evidence regarding the efficacy of particle therapy that will progressively be used to treat a broader number of indications. Therefore, there is now a clear positive stance on the future of the proton therapy market, and this technology is becoming a real part of the global radiotherapy world.

A complete analysis of the Global Proton Therapy market is provided in the third edition of the renowned World Proton Therapy market report which features in a 250-page document a comprehensive review of the market dynamics on a world basis. This report analyzes both past and future trends up to the year 2030, and contains a detailed profile of 20 promoters, manufacturers or developers of proton and carbon therapy equipment.

More information and table of contents are available at:

<http://medraysintell.com/Protontherapy.html>

About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell was founded in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in nuclear medicine, proton therapy and radiotherapy. We aim to form an international team of experts in the field of medical radiation to provide strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the market – the competitive environment as well as the potential for mergers and acquisitions (M&A) – and technology development. MEDraysintell supports the decision process of manufacturers of radiopharmaceuticals and therapeutic radioisotopes, suppliers of equipment and software and members of the investor community. www.medraysintell.com

For general enquiries, please email contact@medraysintell.com.

Contact

Paul-Emmanuel Goethals, MBA
Louvain-la-Neuve, Belgium
e-Mail: peg@medraysintell.com
Mobile: +32 491 080 968

Richard Zimmermann, PhD
Lalaye, France
e-Mail: rz@medraysintell.com
Mobile: +33 6 82 80 06 00